Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - atazanavir sulfate, quantity: 170.85 mg (equivalent: atazanavir, qty 150 mg) - capsule - excipient ingredients: purified water; hydrophobic colloidal silica anhydrous; sodium starch glycollate type a; magnesium stearate; lactose monohydrate; titanium dioxide; indigo carmine; gelatin - atazanavir is indicated for the treatment of hiv 1 infection, in combination with other antiretroviral agents. ,this indication is based on analyses of plasma hiv-1 rna levels and cd4 cell counts from controlled studies

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - atazanavir sulfate, quantity: 227.8 mg (equivalent: atazanavir, qty 200 mg) - capsule - excipient ingredients: sodium starch glycollate type a; lactose monohydrate; purified water; hydrophobic colloidal silica anhydrous; magnesium stearate; titanium dioxide; indigo carmine; gelatin - atazanavir is indicated for the treatment of hiv 1 infection, in combination with other antiretroviral agents. ,this indication is based on analyses of plasma hiv-1 rna levels and cd4 cell counts from controlled studies

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - atazanavir sulfate, quantity: 170.85 mg (equivalent: atazanavir, qty 150 mg) - capsule - excipient ingredients: hydrophobic colloidal silica anhydrous; lactose monohydrate; purified water; sodium starch glycollate type a; magnesium stearate; titanium dioxide; indigo carmine; gelatin - atazanavir is indicated for the treatment of hiv 1 infection, in combination with other antiretroviral agents. ,this indication is based on analyses of plasma hiv-1 rna levels and cd4 cell counts from controlled studies

Australia - English - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - atazanavir sulfate, quantity: 341.7 mg (equivalent: atazanavir, qty 300 mg) - capsule - excipient ingredients: lactose monohydrate; crospovidone; magnesium stearate; titanium dioxide; brilliant blue fcf; purified water; iron oxide yellow; iron oxide red; erythrosine; gelatin; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; shellac; strong ammonia solution; iron oxide black; potassium hydroxide - atazanavir is indicated for the treatment of hiv 1 infection, in combination with other antiretroviral agents. this indication is based on analyses of plasma hiv-1 rna levels and cd4 cell counts from controlled studies (see clinical trials).

Australia - English - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - atazanavir sulfate, quantity: 227.8 mg (equivalent: atazanavir, qty 200 mg) - capsule - excipient ingredients: lactose monohydrate; crospovidone; magnesium stearate; titanium dioxide; brilliant blue fcf; purified water; erythrosine; gelatin; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; shellac; strong ammonia solution; iron oxide black; potassium hydroxide - atazanavir is indicated for the treatment of hiv 1 infection, in combination with other antiretroviral agents. this indication is based on analyses of plasma hiv-1 rna levels and cd4 cell counts from controlled studies (see clinical trials).

Australia - English - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - atazanavir sulfate, quantity: 170.85 mg (equivalent: atazanavir, qty 150 mg) - capsule - excipient ingredients: lactose monohydrate; crospovidone; magnesium stearate; titanium dioxide; brilliant blue fcf; purified water; iron oxide yellow; erythrosine; gelatin; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; shellac; strong ammonia solution; iron oxide black; potassium hydroxide - atazanavir is indicated for the treatment of hiv 1 infection, in combination with other antiretroviral agents. this indication is based on analyses of plasma hiv-1 rna levels and cd4 cell counts from controlled studies (see clinical trials).

United States - English - NLM (National Library of Medicine)

e.r. squibb & sons, l.l.c. - atazanavir sulfate (unii: 4mt4vie29p) (atazanavir - unii:qzu4h47a3s), cobicistat (unii: lw2e03m5pg) (cobicistat - unii:lw2e03m5pg) - atazanavir 300 mg - evotaz® is indicated in combination with other antiretroviral agents for the treatment of human immunodeficiency virus (hiv-1) infection in the following populations [see dosage and administration (2.2, 2.3)] : use of evotaz in treatment-experienced patients should be guided by the number of baseline primary protease inhibitor resistance substitutions [see clinical pharmacology (12.4) ] . the concomitant use of evotaz and the following drugs in table 1, are contraindicated due to the potential for serious and/or life-threatening events or loss of therapeutic effect [see warnings and precautions (5.8, 5.9), drug interactions (7), and clinical pharmacology (12.3)]. evotaz is contraindicated: table 1: drugs contraindicated with evotaz alpha 1-adrenoreceptor antagonist alfuzosin antianginal ranolazine antiarrhythmics dronedarone anticonvulsants carbamazepine, phenobarbital, phenytoin antigout colchicine (when used in patients with hepatic and/or renal impairment) antimycobacterials rifampin antineoplastics irino

United States - English - NLM (National Library of Medicine)

e.r. squibb & sons, l.l.c. - atazanavir sulfate (unii: 4mt4vie29p) (atazanavir - unii:qzu4h47a3s) - atazanavir 150 mg - reyataz® is indicated in combination with other antiretroviral agents for the treatment of hiv-1 infection in adults and in pediatric patients 3 months and older weighing at least 5 kg. limitations of use: reyataz is contraindicated: table 6 displays drugs that are contraindicated with reyataz. drug class drugs within class that are contraindicated with reyataz alpha 1-adrenoreceptor antagonist alfuzosin anticonvulsants carbamazepine, phenobarbital, phenytoin antiarrhythmics amiodarone (with ritonavir), quinidine (with ritonavir) antimycobacterials rifampin antineoplastics apalutamide, encorafenib, irinotecan, ivosidenib antipsychotics lurasidone (with ritonavir), pimozide benzodiazepines orally administered midazolama , triazolam ergot derivatives dihydroergotamine, ergonovine, ergotamine, methylergonovine gi motility agent cisapride hepatitis c direct-acting antivirals elbasvir/grazoprevir; glecaprevir/pibrentasvir herbal products st. john’s wort (hypericum perforatum) lipid-modifying agents: lomitapide, l

European Union - English - EMA (European Medicines Agency)

krka, d.d., novo mesto - atazanavir (as sulfate) - hiv infections - antivirals for systemic use - atazanavir krka capsules, co-administered with low dose ritonavir, are indicated for the treatment of hiv-1 infected adults and paediatric patients 6 years of age and older in combination with other antiretroviral medicinal products.based on available virological and clinical data from adult patients, no benefit is expected in patients with strains resistant to multiple protease inhibitors (≥ 4 pi mutations).the choice of atazanavir krka in treatment experienced adult and paediatric patients should be based on individual viral resistance testing and the patient’s treatment history.

Australia - English - Department of Health (Therapeutic Goods Administration)

bristol-myers squibb australia pty ltd - atazanavir sulfate, quantity: 227.79 mg (equivalent: atazanavir, qty 200 mg) - capsule, hard - excipient ingredients: magnesium stearate; lactose monohydrate; crospovidone; titanium dioxide; propylene glycol; butan-1-ol; isopropyl alcohol; strong ammonia solution; pharmaceutical glaze; dimeticone; indigo carmine; potable water; gelatin; sodium lauryl sulfate - reyataz is indicated for the treatment of hiv 1 infection, in combination with other antiretroviral agents. this indication is based on analyses of plasma hiv-1 rna levels and cd4 cell counts from controlled studies (see 5.1 pharmacodynamic properties: clinical trials).